next generation ex vivo t-cell therapies
next generation ex vivo t-cell therapies: developed by 1 company. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prime Medicine, Inc. (PRME) | Preclinical |
Get deeper analysis on next generation ex vivo t-cell therapies
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis